Background- The use of cytokine-blocking agents has been proposed to modulate the inflammatory response in patients with COVID19. Tocilizumab and Anakinra were included in the local protocol as an optional treatment in critically ill patients with acute respiratory distress syndrome (ARDS) by SARS-CoV2 infection. This cohort study evaluated the effects of therapy with cytokine blocking agents on in-hospital mortality in COVID19 patients requiring mechanical ventilation and admitted to intensive care unit. Methods- The association between therapy with Tocilizumab or Anakinra and in-hospital mortality was assessed in consecutive adult COVID19 patients admitted to our ICU with moderate to severe ARDS. The association was evaluated by comparin...
Background: The severity of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection i...
Objective: To evaluate the effectiveness of Tocilizumab (with or without corticosteroids) in a real-...
International audienceLittle is known about the immuno-inflammatory response to Tocilizumab and its ...
Background- The use of cytokine-blocking agents has been proposed to modulate the inflammatory respo...
OBJECTIVE: To examine outcomes among patients who were treated with the targeted anti-cytokine agent...
Background: Cytokine release storm (CRS) in severe acute respiratory syndrome coronavirus-2 (SARS Co...
Background and Objectives: Mortality and illness due to COVID-19 have been linked to a condition kno...
Introduction: Severe COVID-19 cases have a detrimental hyper-inflammatory host response and differen...
CONTEXT: Tocilizumab (TCZ), an interleukin-6 (IL-6) receptor antagonist, has been approved for use i...
Tocilizumab decreases inflammatory response in the cytokine storm which is one of the mechanisms beh...
Background: Cytokine storm is a marker of COVID-19 illness severity and increased mortality. Immunom...
(1) Background: Severe COVID-19 outcomes are associated with cytokine release syndrome, characterize...
BACKGROUND: Infections with SARS-CoV-2 continue to cause significant morbidity and mortality. Interl...
A subgroup of patients with SARS-CoV-2 infection was thought to have developed cytokine release synd...
Objectives: To prospectively investigate in patients with severe COVID-19-associated cytokine storm ...
Background: The severity of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection i...
Objective: To evaluate the effectiveness of Tocilizumab (with or without corticosteroids) in a real-...
International audienceLittle is known about the immuno-inflammatory response to Tocilizumab and its ...
Background- The use of cytokine-blocking agents has been proposed to modulate the inflammatory respo...
OBJECTIVE: To examine outcomes among patients who were treated with the targeted anti-cytokine agent...
Background: Cytokine release storm (CRS) in severe acute respiratory syndrome coronavirus-2 (SARS Co...
Background and Objectives: Mortality and illness due to COVID-19 have been linked to a condition kno...
Introduction: Severe COVID-19 cases have a detrimental hyper-inflammatory host response and differen...
CONTEXT: Tocilizumab (TCZ), an interleukin-6 (IL-6) receptor antagonist, has been approved for use i...
Tocilizumab decreases inflammatory response in the cytokine storm which is one of the mechanisms beh...
Background: Cytokine storm is a marker of COVID-19 illness severity and increased mortality. Immunom...
(1) Background: Severe COVID-19 outcomes are associated with cytokine release syndrome, characterize...
BACKGROUND: Infections with SARS-CoV-2 continue to cause significant morbidity and mortality. Interl...
A subgroup of patients with SARS-CoV-2 infection was thought to have developed cytokine release synd...
Objectives: To prospectively investigate in patients with severe COVID-19-associated cytokine storm ...
Background: The severity of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection i...
Objective: To evaluate the effectiveness of Tocilizumab (with or without corticosteroids) in a real-...
International audienceLittle is known about the immuno-inflammatory response to Tocilizumab and its ...